Pioglitazone for the treatment of type 2 diabetes in patients inadequately controlled on insulin

References

• Stratton IM Adler AI Neil HAW for the UK Prospective Diabetes Study Group Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study BMJ 2000 321 405 412 10938048
   PubMed Web of Science ®Google Scholar
• Brownlee M The pathobiology of diabetic complications: a unifying mechanism Diabetes 2005 54 6 1615 1625 15919781
   PubMed Web of Science ®Google Scholar
• Prokopenko I McCarthy MI Lindgren CM Type 2 diabetes: new genes, new understanding Trends Genet 2008 24 12 613 621 18952314
   PubMed Web of Science ®Google Scholar
• The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus N Engl J Med 1993 329 14 977 986 8366922
   PubMed Web of Science ®Google Scholar
• The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes N Engl J Med 2005 353 25 2643 2653 16371630
   PubMed Web of Science ®Google Scholar
• Gaede P Lund-Andersen H Parving HH Pedersen O Effect of a multifactorial intervention on mortality in type 2 diabetes N Engl J Med 2008 358 6 580 591 18256393
   PubMed Web of Science ®Google Scholar
• Duckworth W Abraira C Moritz T for the VADT Investigators Glucose control and vascular complications in veterans with type 2 diabetes N Engl J Med 2009 360 2 129 139 19092145
   PubMed Web of Science ®Google Scholar
• ADVANCE Collaborative Group Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes N Engl J Med 2008 358 24 2560 2572 18539916
   PubMed Web of Science ®Google Scholar
• Action to Control Cardiovascular Risk in Diabetes Study Group Effects of intensive glucose lowering in type 2 diabetes N Engl J Med 2008 358 24 2545 2559 18539917
   PubMed Web of Science ®Google Scholar
• Weiss IA Valiquette G Schwarcz MD Impact of glycemic treatment choices on cardiovascular complications in type 2 diabetes Cardiol Rev 2009 14 4 165 175 19525678
   PubMed Web of Science ®Google Scholar
• Ceriello A Postprandial hyperglycemia and cardiovascular disease. Is the HEART2D study the answer? Diabetes Care 2009 32 3 521 522 19246590
   PubMed Web of Science ®Google Scholar
• Mannucci E Monami M Lamanna C Gori F Marchionni N Prevention of CVD through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical trials Nutr Metab Cardiovasc Dis 2009 19 9 604 612 19427768
   PubMed Web of Science ®Google Scholar
• Mazzone T Chait A Plutzky J Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies [review.] Lancet 2008 371 9626 1800 1809 18502305
   PubMed Web of Science ®Google Scholar
• Schwartz S Targeting the pathophysiology of type 2 diabetes: rationale for combination therapy with pioglitazone and exenatide Curr Med Res Opin 2008 Sep 30 Epub ahead of print
   Web of Science ®Google Scholar
• Haffner SF D’Agostino RJr Mykkänen L Insulin sensitivity in subjects with type 2 diabetes. Relationship to cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study Diabetes Care 1999 22 4 562 568 10189532
   PubMed Web of Science ®Google Scholar
• Kendall DM Bergenstal RM Educational Review Manual in Endocrinology, Diabetes and Metabolism. Focus: Diabetes 3rd ed New York Castle Connolly Graduate Medical Publishing 2009
   Google Scholar
• Goldstein BJ Insulin resistance as the core defect in type 2 diabetes mellitus Am J Cardiol 2002 90 Suppl G3 G10
   Google Scholar
• Kahn SE The importance of β-cell failure in the development and progression of type 2 diabetes J Clin Endocrinol Metab 2001 86 9 4047 4058 11549624
   PubMed Web of Science ®Google Scholar
• Kaiser N Leibowitz G Nesher R Glucotoxicity and β-cell failure in type 2 diabetes mellitus J Pediatr Endocrinol Metab 2003 16 1 5 22 12585335
   PubMed Web of Science ®Google Scholar
• Scheen A Combined thiazolidinedione-insulin therapy: should we be concerned about safety? Drug Saf 2004 27 12 841 856 15366973
   PubMed Web of Science ®Google Scholar
• DeFronzo R ACTos NOW for the prevention of diabetes (ACT NOW) study Paper presented at: American Diabetes Association Meeting 2008 June 11 San Francisco, CA
   Google Scholar
• Buchanan TA Xiang AH Peters RK Preservation of pancreatic beta cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women Diabetes 2002 51 9 2796 2803 12196473
   PubMed Web of Science ®Google Scholar
• Kahn SE Haffer SM Heise MA Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy N Engl J Med 2006 355 23 2427 2443 17145742
   PubMed Web of Science ®Google Scholar
• Goldberg RB Kendall DM Deeg MA A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia Diabetes Care 2005 28 7 1547 1554 15983299
   PubMed Web of Science ®Google Scholar
• ACTOS Prescribing Information http://www.actos.com/actospro/prescribinginfo.aspx Accessed January 21, 2010
   Google Scholar
• Nesto RW Bell D Bonow RO for the American Heart Association; American Diabetes Association Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003 Circulation 2003 108 23 2941 2948 14662691
   PubMed Web of Science ®Google Scholar
• Bell DS Heart failure: the frequent, forgotten, and often fatal complication of diabetes Diabetes Care 2003 26 8 2433 2441 12882875
   PubMed Web of Science ®Google Scholar
• Masoudi FA Inzucchi SE Wang Y Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study Circulation 2005 111 5 583 590 15699279
   PubMed Web of Science ®Google Scholar
• Yang T Soodvilai S Renal and vascular mechanisms of thiazolidinedione-induced fluid retention PPAR Res 2008 2008 943614 10.1155/2008/943614 18784848
   PubMed Web of Science ®Google Scholar
• Zib I Jacob AN Lingvay I Effect of pioglitazone therapy on myocardial and hepatic steatosis in insulin-treated patients with type 2 diabetes J Investig Med 2007 55 5 230 236
   PubMed Web of Science ®Google Scholar
• Naoumova RP Kindler H Leccisotti L Pioglitazone improves myocardial blood flow and glucose utilization in nondiabetic patients with combined hyperlipidemia: a randomized, double-blind, placebo-controlled study J Am Coll Cardiol 2007 50 21 2051 2058 18021872
   PubMed Web of Science ®Google Scholar
• Dormandy JA Charbonnel B Eckland DJA Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial 2005 Lancet 2005 366 9493 1279 1289 16214598
   PubMed Web of Science ®Google Scholar
• Lincoff AM Wolski J Nicholls SJ Nissen SE Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus a meta-analysis of randomized trials JAMA 2007 298 10 1180 1188 17848652
   PubMed Web of Science ®Google Scholar
• Nissen SE Wolski K Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N Engl J Med 2007 356 24 2457 2471 17517853
   PubMed Web of Science ®Google Scholar
• Richter B Bandeira-Echtler E Bergerhoff K Clar C Ebrahim SH Rosiglitazone for type 2 diabetes mellitus Cochrane Database Syst Rev [review] 2007 18 3 CD006063 17636824
   PubMed Web of Science ®Google Scholar
• Juurlink DN Gomes T Lipscombe LL Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study BMJ 2009 339 b2942 19690342
   PubMed Web of Science ®Google Scholar
• Tzoulaki I Molokhia M Curcin V Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database BMJ 2009 339 b4731 19959591
   PubMed Web of Science ®Google Scholar
• Hsiao A Worrall DS Olefsky JM Subramaniam S Variance-modeled posterior inference of microarray data: detecting gene-expression changes in 3T3-L1 adipocytes Bioinformatics 2004 20 17 3108 3127 15217816
   PubMed Web of Science ®Google Scholar
• Camp HS Li O Wise SC Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone Diabetes 2000 49 4 539 547 10871190
   PubMed Web of Science ®Google Scholar
• Mudaliar S Chang AR Aroda VR Effects of intensive insulin therapy alone and with added pioglitazone on renal salt/water balance and fluid compartment shifts in type 2 diabetes Diabetes Obes Metab 2010 12 2 133 138 19889003
   PubMed Web of Science ®Google Scholar
• Kushner RF Sujak M Prevention of weight gain in adult patients treated with pioglitazone Obesity (Silver Spring) 2009 17 5 1017 1022 19180065
   PubMed Web of Science ®Google Scholar
• Gupta AK Smith SR Greenway FL Bray GA Pioglitazone treatment in type 2 diabetes mellitus when combined with portion control diet modifies the metabolic syndrome Diabetes Obes Metab 2009 11 4 330 337 19267711
   PubMed Web of Science ®Google Scholar
• Mar tens FM Vi s seren FL Lemay J Metabolic and additional vascular effects of thiazolidinediones Drugs 2002 62 10 1463 1480 12093315
   PubMed Web of Science ®Google Scholar
• Einhorn D Rendell M Rosenzweig J Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group Clin Ther 2000 22 12 1395 1409 11192132
   PubMed Web of Science ®Google Scholar
• Fonseca V Rosenstock J Patwardhan R Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial JAMA 2000 283 13 1695 1702 10755495
   PubMed Web of Science ®Google Scholar
• Zinman B Hoogwerf BJ Duran Garcia S The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial Ann Intern Med 2007 146 477 485 17404349
   PubMed Web of Science ®Google Scholar
• Schwartz AV TZDs and bone: a review of the recent clinical evidence PPAR Res 2008 2008 297893 18795105
   PubMed Web of Science ®Google Scholar
• Takeda Pharmaceuticals Observation of an increased incidence of fractures in female patients who received long-term treatment with ACTOS (pioglitazone HCl) tablets for type 2 diabetes mellitus Dear Healthcare Provider letter Available from: http://www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/UCM153896.pdf Accessed January 31, 2010
   Google Scholar
• Clar C Royle P Waugh N Adding pioglitazone to insulin containing regimens in type 2 diabetes: systematic review and meta-analysis PLoS 2009 4 7 e6112
   Web of Science ®Google Scholar
• Rodbard HW Jellinger PS Davidson JA Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control Endocr Pract 2009 15 6 540 559 19858063
   PubMed Web of Science ®Google Scholar
• Nathan DM Kuenen J Borg R for the A1c-Derived Average Glucose (ADAG) Study Group Translating the A1C assay into estimated average glucose values Diabetes Care 2008 31 12 1473 1478 18540046
   PubMed Web of Science ®Google Scholar
• Margolis DJ Hoffstad O Strom BL Association between serious ischemic cardiac outcomes and medications used to treat diabetes Pharmacoepidemiol Drug Saf 2008 17 8 753 759 18613215
   PubMed Web of Science ®Google Scholar
• Aljabri K Kozak SE Thompson DM Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial Am J Med 2004 116 4 230 235 14969650
   PubMed Web of Science ®Google Scholar
• Raz I Stranks S Filipczak R Efficacy and safety of biphasic insulin aspart 30 combined with pioglitazone in type 2 diabetes poorly controlled on glibenclamide (glyburide) monotherapy or combination therapy: an 18 week, randomized, open-label study Clin Ther 2005 27 9 1432 1443 16291416
   PubMed Web of Science ®Google Scholar
• Rosenstock J Sugimoto D Strange P Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naïve patients Diabetes Care 2006 29 3 554 559 16505505
   PubMed Web of Science ®Google Scholar
• Dorkhan M Frid A Groop L Differences in effects of insulin glargine or pioglitazone added to oral anti-diabetic therapy in patients with type 2 diabetes: what to add—insulin glargine or pioglitazone? Diabetes Res Clin Pract 2008 82 3 340 345 18926586
   PubMed Web of Science ®Google Scholar
• Yamanouchi Concomitant therapy with pioglitazone and insulin for the treatment of type 2 diabetes Vasc Health Risk Manag 2010 6 189 197 20407626
   PubMedGoogle Scholar
• Berhanu P Perez A Yu S Effect of pioglitazone in combination with insulin therapy on glycaemic control, insulin dose requirement and lipid profile in patients with type 2 diabetes previously poorly controlled with combination therapy Diabetes Obes Metab 2006 9 4 512 520 17587394
   PubMed Web of Science ®Google Scholar
• Charbonnel B DeFronzo R Davidson J Pioglitazone use in combination with insulin in the prospective pioglitazone clinical trial in macrovascular events study (PROactive19) J Clin Endocrinol Metab 2010 95 5 2163 2171 20237169
   PubMed Web of Science ®Google Scholar
• Mitri J Hamdy O DeFronzo RA Diabetes medications and body weight Expert Opin Drug Saf 2009 8 5 573 584 19538102
   PubMed Web of Science ®Google Scholar
• DeFronzo RA Pharmacologic therapy for type 2 diabetes mellitus Ann Intern Med 1999 131 14 281 303 10454950
   PubMed Web of Science ®Google Scholar
• Nathan DM Initial management of glycemia in type 2 diabetes mellitus N Engl J Med 2002 347 17 1342 1349 12397193
   PubMed Web of Science ®Google Scholar
• Rosenstock J Einhorn D Hershon K for the Pioglitazone 014 Study Group Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving dione derivative improves fat distribution and multiple risk factors in subjects with visceral fat accumulation: double-blind placebo-controlled trial Diabetes Res Clin Pract 2001 54 3 181 190 11689273
   PubMed Web of Science ®Google Scholar
• Rosenstock J Einhorn D Hershon K Glazer NB Yu S for Pioglitazone 014 Study Group Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy Int J Clin Pract 2002 56 4 251 257 12074206
   PubMed Web of Science ®Google Scholar
• Mattoo V Eckland D Widel M for H6E-MC-GLAT study group Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study Clin Ther 2005 27 5 554 567 15978304
   PubMed Web of Science ®Google Scholar
• Davidson JA Perez A Zhang J for the Pioglitazone 343 Study Group Addition of pioglitazone to stable insulin therapy in patients with poorly controlled type 2 diabetes: results of a double-blind, multicentre, randomized study Diabetes Obes Metab 2006 8 2 164 174 16448520
   PubMed Web of Science ®Google Scholar
• Schmitz O Charbonnel B Scheen A Pioglitazone reduces insulin requirements and improves glycemic control in insulin-treated patients with type 2 diabetes: results from PROactive Poster presented at: The European Diabetes Association Conference 2006 Sep 14–17 Copenhagen, Denmark
   Google Scholar
• Okamoto T Okamoto L Lisanti MP Akishita M Switch to oral hypoglycemic agent therapy from insulin injection in patients with type 2 diabetes Geriatr Gerontol Int 2008 8 4 218 226 19149832
   PubMed Web of Science ®Google Scholar
• Langenfeld M Forst T Hohberg C Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus Circulation 2005 111 19 2525 2531 15883215
   PubMed Web of Science ®Google Scholar
• Watanabe I Tani S Anazawa T Pioglitazone on arteriosclerosis in comparison with that of glibenclamide Diabetes Res Clin Pract 2005 68 2 104 110 15860237
   PubMed Web of Science ®Google Scholar
• McGuire D Newby L Bhapkar M Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes Am Heart J 2004 147 2 246 252 14760321
   PubMed Web of Science ®Google Scholar
• Despres J Lamarche B Mauriege P Hyperinsulinemia as an independent risk factor for ischemic heart disease N Engl J Med 1996 334 15 952 957 8596596
   PubMed Web of Science ®Google Scholar
• Wilcox R Bousser M Betteridge D Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspectivepioglitAzone Clinical Trial In macroVascular Events 04) Stroke 2007 38 3 865 873 17290029
   PubMed Web of Science ®Google Scholar